Table 1 Clinical characteristics, response, and toxicity profile of patients
Patient | Age (years) | Sex | Cancer and stage | Prior PD-1 inhibitors therapy | ECOG /PS | Best response | Toxicity (grade) | Other treatments combine with PD-1 inhibitors | PD-1 inhibitors treatments and cycles | Time since treatment initiation (months) | Alive or dead |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 57 | M | LCLC IV | Chemotherapy + targeted cancer therapy | 1 | SD | Pneumonitis (4) Leukopenia (2) Hemiparesthesia (2) Granulocytopenia (1) Anemia (1) Thrombocytopenia (1) Hyperglycemia (1) Elevated transaminase (1) Convulsions Dizzy | None | Sintilimab (10 cycles) | 7.2 | D (Pneumonitis) |
2 | 46 | M | DLBCL II | Chemotherapy + targeted cancer therapy | 0 | PD | Anemia (2) Thrombocytopenia (2) Leukopenia (1) Hyperglycemia (1) | Chemotherapy + targeted cancer therapy | Sintilimab (6 cycles and ongoing) | 5.1 | Alive |
3 | 29 | M | BL IV | Chemotherapy + surgery | 3 | SD | Leukopenia (4) Granulocytopenia (4) Thrombocytopenia (3) Dyskinesia(3) Septicemia(3) Anemia (2) Pneumonitis (2) Rash (2) Hyperglycemia (1) | Chemotherapy | Sintilimab (34 cycles and ongoing) | 27.8 | Alive |
4 | 62 | M | SCLC IV | Chemotherapy | 0 | SD | Anemia (1) Mouth ulcers (1) | Chemotherapy | Sintilimab (2 cycles and refuse treatment) | 18.3 | Alive |
5 | 69 | M | SCLC IV | Chemotherapy | 1 | PD | Anemia (2) Nausea (2) Vomit (2) Hypoglycemia (1) Hypokalemia (1) Hemiparesthesia (1) | Chemotherapy | Sintilimab (3 cycles and refuse treatment) | NA | NA |
6 | 38 | M | BL IV | Chemotherapy + targeted cancer therapy + iNKT cell therapy | 0 | SD | Septicemia(4) Anemia (3) Hyperglycemia (1) Diarrhea (1) | Chemotherapy + targeted cancer therapy | Sintilimab (2 cycles) | 1.9 | D (Septicemia) |
7 | 50 | M | HL IV | Chemotherapy | 0 | SD | Hyperglycemia (1) | None | Sintilimab (31 cycles and ongoing) | 26.1 | Alive |
8 | 34 | M | NHL IV | Chemotherapy + targeted cancer therapy | 0 | PD | Anemia (3) Septicemia(3) Leukopenia (2) Granulocytopenia (1) Thrombocytopenia (1) Hyperglycemia (1) | None | Sintilimab (4 cycles and ongoing) | 3.8 | Alive |
9 | 39 | M | DLBCL IV | Chemotherapy + targeted cancer therapy + radiotherapy | 1 | SD | Septicemia(4) Anemia (3) Nausea (2) Hyperglycemia (1) Fatigue (1) Hypokalemia (1) | Chemotherapy | Sintilimab (3 cycles) | 3.7 | D (Septicemia) |
10 | 32 | M | HL II | Chemotherapy | 0 | NA | Leukopenia (1) Granulocytopenia (1) | None | Nivolumab (4 cycles and refuse treatment) | 39.9 | Alive |
11 | 43 | M | DLBCL II | Chemotherapy + targeted cancer therapy | 1 | PD | Leukopenia (4) Granulocytopenia (3) Anemia (3) Thrombocytopenia (2) Hyperglycemia (2) Soft tissue infection (2) Rash (2) Hematochezia (1) | Chemotherapy + targeted cancer therapy | Sintilimab (2 cycles and ongoing) | 1.7 | Alive |
12 | 44 | M | DLBCL IV | Chemotherapy + targeted cancer therapy + radiotherapy | 1 | NA* | Anemia (4) Septicemia(4) urinary tract infection (1) | Targeted cancer therapy | Sintilimab (1 cycles) | 1.2 | D (Septicemia) |
13 | 40 | M | NPC II | Chemotherapy + radiotherapy | 1 | SD | Anemia (2) Rash (2) Hearing loss (2) Leukopenia (1) Elevated transaminase (1) Fatigue (1) | Chemotherapy | Sintilimab (9 cycles and ongoing) | 6.3 | Alive |
14 | 56 | M | SCLC IV | Chemotherapy | 1 | NA* | Weight loss (2) Fatigue (1) Pneumonitis (1) | Chemotherapy | Camrelizumab (1 cycles and ongoing) | 1.7 | Alive |
15 | 64 | M | SCLC IV | Chemotherapy | 1 | PR | Anemia (4) Septicemia(4) Granulocytopenia (3) Dyskinesia (3) Leukopenia (2) Elevated transaminase (2) Weight loss (2) Leukopenia (1) | Chemotherapy | Camrelizumab (7 cycles) | 6.2 | D (Septicemia) |